Monoclonal Antibody Therapy in Sinonasal Disease

Chiarella, Sergio E.; Sy, Hendrik; Peters, Anju T.

doi:10.2500/ajra.2017.31.4412

Cited by 13 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bei Krankheitspersistenz erfolgen mehrwöchige systemische Kortikosteroid-Gaben zusätzlich zur Basistherapie, was gelegentlich als maximale medikamentöse Therapie bezeichnet wird. Ist die Erkrankung auch hierunter refraktär, ist eine chirurgische Intervention oft hilfreich [5,12]. In einer prospektiven Beobachtungsstudie wurden 4 standardisierte Behandlungsmethoden bei Patienten mit CRS untersucht, wel-che primär auf eine maximale medikamentöse Therapie nicht ansprachen.…”

Section: Herkömmliche Therapieoptionenunclassified

“…Außerdem fördert es die Reifung, Rekrutierung, Aktivierung und das Überleben von eosinophilen Granulozyten im Gewebe. Außer von T H 2-Zellen wird es von zahlreichen weiteren Zellen produziert, einschließlich Mastzellen, CD34 +-Vorläufer-T-Zellen, natürlichen Killer-T-Zellen und von Eosinophilen selbst [12]. IL-5 wird bei Patienten mit CRSwNP in hohen Konzentrationen im Sekret und in der Schleimhaut nachgewiesen [1,11] und spielt eine wichtige Rolle in der Pathogenese der CRSwNP [6].…”

Section: Interleukin 5 (Il-5)unclassified

“…Nachdem es nach 16-wöchiger Therapie zu einer weiteren Reduktion der NP kommt, sollte die Behandlung bei Respondern längerfristig bis fortlaufend erfolgen[7]. Omalizumab führt bei Patienten mit CRSwNP und schwerem Asthma einerseits zur Besserung des Krankheitsverlaufs oder zumindest zu einer Stabilisierung und stellt somit eine wichtige Alternative in der Therapie der CRS dar[12]. Biologika: Dosierungen, Anwendungsdauer und Nebenwirkungen.…”

unclassified

See 2 more Smart Citations

Biologika bei chronischer Rhinosinusitis

Pinggera¹,

Innerhofer²,

Fischer³

et al. 2020

Laryngorhinootologie

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) is an inflammation of the nasal and paranasal mucosa, lasting for more than 12 weeks. By now approximately 15 % of the European and American population are affected, which indicates that CRS is a serious health problem. Beside other subgroups the most important classification is CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). Standard-of-care therapies include nasal saline solution as well as topic or systemic corticosteroids. If this does not lead to a sufficient recovery, surgical therapy is a good option. A new therapy option is represented by biologics, particularly monoclonal antibodies (mAB). They are well-established for treatment of asthma bronchiale. Due to the fact that asthma is often associated with nasal polyps, and mAB may could also lead to improvements in CRS, studies were conducted. In the meantime there is a number of mAB which have emerged as an alternative treatment for patients with CRSwNP.

show abstract

Section: Herkömmliche Therapieoptionenunclassified

Section: Interleukin 5 (Il-5)unclassified

unclassified

See 1 more Smart Citation

Biologika bei chronischer Rhinosinusitis

Pinggera¹,

Innerhofer²,

Fischer³

et al. 2020

Laryngorhinootologie

View full text Add to dashboard Cite

show abstract

“…However, constant nasal tissue eosinophilia is connected with reappearance of nasal polyps. 21 Augmented IgE levels and secretion from local polyclonal IgE production in nasal polyp tissue have been demonstrated in a few studies and linked with disease severity. 22 As nasal polyposis is an example of Th2-type dominant disorder, proof-of-concept trials and case reports investigating the Omab effects on nasal polyps are of interest.…”

Section: Omalizumab Use In Nasal Polyposismentioning

confidence: 99%

Untitled

2018

MOJI

View full text Add to dashboard Cite

Here, recent literature on the use of omalizumab in sino-nasal allergic diseases is reviewed. Omalizumab is an anti-human IgE humanized monoclonal antibody produced against CƐ3 domain of the Fc fragment of IgE molecule. Omalizumab suppresses the effector functions of IgE by preventing binding to high-affinity receptors (FcεR1) on allergy related immune effector cells, blocking mast cell or basophil mediator release. Omalizumab is helpful mainly in ragweed/birch pollen-induced seasonal and perennial allergic rhinitis rather than uncontrolled and concomitant allergic rhinitis and asthma/chronic rhino-sinusitis/nasal polyposis.

show abstract

“…That approach has not been widely adopted in the treatment of chronic rhinosinusitis, but several monoclonal antibodies, including omalizumab, dupilumab, mepolizumab, and reslizumab, are emerging as therapeutic alternatives to conventional therapies of corticosteroids and even surgery. In this issue, Chiarella et al, 4 presented a comprehensive review of clinical trials of these agents for the treatment of specific chronic rhinosinusitis subtypes.…”

Section: Medical Treatment Of Sinonasal Inflammatory Conditionsmentioning

confidence: 99%

21st Century Rhinology

2017

Am J Rhinol�Allergy

View full text Add to dashboard Cite

21st century rhinology T wenty-first century rhinology encompasses both medical and surgical treatments of a wide range of diseases and conditions of the nose, paranasal sinuses, and adjacent structures. Now under the leadership of coeditors Rakesh Chandra, M.D., and Raj Sindwani, M.D., as well as Deputy Editor of Allergy Anju Peters, M.D., the American Journal of Rhinology and Allergy, as a leading otorhinolaryngology journal, captures the breath of the field in articles submitted by authors from across the entire world. BASIC SCIENCEAlthough a role for the use of doxycycline has emerged in the treatment of chronic rhinosinusitis, the mechanisms for the antibiotic's anti-inflammatory effects are poorly understood. Shin et al. 1 examined the effect of doxycycline in an in vitro model of A549 and nasal epithelial cells. They showed that doxycycline inhibited TGF ␤1-induced migration as well as the epithelial to mesenchymal transition.Cigarette smoke adversely impacts sinonasal mucosal function (consistent with its adverse health impacts throughout the body) through various mechanisms. Shin et al. 2 used an in vitro model to examine the impact of cigarette smoke extract (CSE) on nasal fibroblasts. They demonstrated that CSE stimulates VEGF expression through its apparent downregulation of TLR4 transcription. Interesting, pretreatment with reactive oxygen species reduced CSE-initiated VEGF expression. The T2R38 bitter taste receptor has a role in innate immunity mechanisms through nitric oxide production. Yan et al., 3 built on this work and established that both T2R4 and T2R16, two additional bitter taste receptors, were expressed in cilia of human epithelial cells and triggered nitric oxide production.

show abstract

Monoclonal Antibody Therapy in Sinonasal Disease

Cited by 13 publications

References 24 publications

Biologika bei chronischer Rhinosinusitis

Biologika bei chronischer Rhinosinusitis

Untitled

21st Century Rhinology

Contact Info

Product

Resources

About